Seegene pushes for industry's first 'million clinical'... Changing global diagnostic standards

Seegene is taking the lead in the diagnostic industry to establish new testing standards for each disease through a large-scale global clinical study of one million cases.

Global molecular diagnostics company Seegene announced on the 8th that it is pushing forward with the 'Global Million Clinical Study (GMCS)' project. The project will be conducted from August in key countries worldwide, including Korea, and its core is to secure over one million actual clinical data for the first time in the industry to prove the usefulness of disease-specific testing strategies.

GMCS goes beyond the existing single-pathogen-centered testing to verify the clinical value of 'syndromic PCR'-based testing, which simultaneously identifies major causative agents in a single test. It plans to analyze hidden pathogens, co-infections, and genotypes that were difficult to detect with conventional methods, and present a more sophisticated patient management model.

At the center of the research is 'STAgora,' a real-time diagnostic data analysis platform. The accumulated data will be linked to the platform and used as basic data to analyze the patterns of infectious diseases by country and disease, which will become the scientific basis for establishing new global testing standards in the future.

Seegene will verify comprehensive testing strategies for major diseases such as respiratory infections (RP), sexually transmitted infections (STI), human papillomavirus (HPV), and gastrointestinal infections (GI). It plans to compare and analyze the current testing methods in medical settings with the new strategies, and objectively evaluate the value of the additional clinical information obtained in contributing to actual medical decision-making.

In particular, it focuses on reducing diagnostic gaps caused by different medical environments and guidelines across countries. To solve the problem where patients receive different levels of diagnosis for the same disease depending on each country's system, the plan is to establish universal and standardized global standards based on actual data.

Seegene Chairman Cheon Jong-yoon emphasized, "GMCS is a project that goes beyond simple data accumulation to open a new paradigm of diagnosis based on evidence from actual medical settings," and "We will not just stop at developing good technology but will continuously build a scientific foundation so that everyone around the world, regardless of region, can receive the best testing."

Meanwhile, Seegene was recently selected as one of 'TIME's 2026 World's Most Influential Companies' by the U.S. newsweekly Time.

Business Korea reporter Choi Moon-hee (pr@businesskorea.co.kr)